The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
Abstract
A new edition of the WHO classification of tumours of the CNS was published in 2021. Although the previous edition of this classification was published just 5 years earlier, in 2016, rapid advances in our understanding of the molecular underpinnings of CNS tumours, including the diversity of clinically relevant molecular types and subtypes, necessitated a new classification system. Compared with the 2016 scheme, the new classification incorporates even more molecular alterations into the diagnosis of many tumours and reorganizes gliomas into adult-type diffuse gliomas, paediatric-type diffuse low-grade and high-grade gliomas, circumscribed astrocytic gliomas, and ependymal tumours. A number of new entities are incorporated into the 2021 classification, especially tumours that preferentially or exclusively arise in the paediatric population. Such a substantial revision of the WHO scheme will have major implications for the diagnosis and treatment of patients with CNS tumours. In this Perspective, we summarize the main changes in the classification of diffuse and circumscribed gliomas, ependymomas, embryonal tumours and meningiomas, and discuss how each change will influence post-surgical treatment, clinical trial enrolment and cooperative studies. Although the 2021 WHO classification of CNS tumours is a major conceptual advance, its implementation on a routine clinical basis presents some challenges that will require innovative solutions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glioma is the most prevalent central nervous system tumor and is classified into four grades, grades I, II, III, and IV, by the World Health Organization [44].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [44]
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella‐Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,703
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chávez, L., Reuß, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,114
Ostrom, Q. T., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz‐Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,716
Cited by
Sorted by citations
Items 301–314 of 314
Yetişgin, E., Turk, N., Alkan, G. V., & Önder, E. (2026) · Diagnostics · doi:10.3390/diagnostics16172723
Han, J., Ma, Z., Lin, S., & Wu, W. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110465
Yu, X., Wu, R., Huang, T., Tiek, D. M., Walker, M. N., He, Q., Horbinski, C., Hu, B., & Cheng, S. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag213
Self-citationSharma, Y., Parihar, A., Mohan, A. J., Arya, N., Kanwar, R. K., & Agrawal, A. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06180-5
Zhou, P., Guo, C., Shi, Y., Xu, K., Guo, L., Tan, J., Zhao, P., Li, F., & Chen, T. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150561
Antiglioma Effects of Monepantel: Roles of Autophagy and Endoplasmic Reticulum Stress
Sartori, N., dos Santos, G. G. P., da Rosa, V. B., do Nascimento, G. R. S., d’Acampora, J., Garcez, R. C., Pinto‐Junior, V. R., Osterne, V. J. S., Oliveira, M. V., Cavada, B. S., et al. (2026) · Neuroglia · doi:10.3390/neuroglia7040034
Pan, Y., Wu, C., Tan, J., Luo, F., & Wu, Z. (2026) · Biomedicines · doi:10.3390/biomedicines14102216
Ge, X., Mao, Y., Geng, Z., Zou, J., Yan, L., Chen, Y., & Yin, L. (2026) · Research Square · doi:10.21203/rs.3.rs-10973086/v1
Innani, S., Pitarch, C., Majeed, M. M., Harmsen, H. J., Bell, W. R., Makris, D., & Bakas, S. (2026) · Cancers · doi:10.3390/cancers18203259
Hayrani, K. A. Y. A., Aydın, A. A., Umit, A., Guven, O. D., Ünlü, A., Balcıoğlu, F. M., Öztürk, B., Yıldız, M., & Koçer, M. (2026) · Medicina · doi:10.3390/medicina62101958
Bosh miya oʻsmalarining xususiyatlari va zamonaviy diagnostik-davolash yondashuvlari
Saitqulova, A., & Imomova, D. (2026) · doi:10.70413/yo-v4-i70-57894
Medvedovska, Y. V., Chuvashova, O. Y., Glavatskyi, O., & Zemskova, O. V. (2026) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.3.2026.440-470
Carenza, C., Franzese, S., Castagna, A., Terzoli, S., Simonelli, M., Persico, P., Bello, L., Nibali, M. C., Pessina, F., Kunderfranco, P., et al. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10165863
Gao, Y., Yu, Z., Xie, Y., Chen, L., Shi, L., Zhu, R., & Lu, Y. (2026) · IUBMB Life · doi:10.1002/iub.70132
Metadata
- Authors
- Horbinski, C., Berger, T., Packer, R. J., & Wen, P. Y.
- Affiliations
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Children's National (US)
- Corresponding author
- Horbinski, Craig
- Venue
- Nature Reviews Neurology
- Published
- 2022-06-21
- Volume
- 18
- Issue
- 9
- Pages
- 515-529
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W4283213286
- Cited by
- 312
- References
- 125
- Citations by year
- 2026: 59 · 2025: 83 · 2024: 86 · 2023: 71 · 2022: 12
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P50CA221747, K12CA090354)
- National Institute of Neurological Disorders and Stroke (R01NS118039, R01NS102669, R01NS117104)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced Neuroimaging Techniques and Applications
- Keywords
- diffuse glioma, ependymoma, embryonal tumors, meningioma, pediatric brain tumors, inclusion and exclusion criteria, postoperative care
- MeSH terms
- Brain Neoplasms, Child, Glioma, Humans, Meningeal Neoplasms, Meningioma, World Health Organization, Central Nervous System Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
